Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508756-19-00

Acronym

IRST100.39

Enrollment

Registered

2024-08-05

Start date

2019-10-29

Completion date

Unknown

Last updated

2025-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mesothelioma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Italy

None listed

Source: EU CTIS · Data processed: Feb 4, 2026